ProtTech has developed a new technology to determine the complete amino acid sequence of monoclonal antibodies. Due to its large size and its vast diversity in antibody sequences, it used to be an extremely difficult task to carry out the de novo sequencing of such a large protein. Recently, with the breakthrough we achieved, we are capable to determine the complete sequence* of a mAb with as low as 100 ug sample of some moderate purity (>85%). 

This new technology will have a significant impact on the discovery of novel therapeutic antibodies, as well as on the development of the generic or biosimilar antibody drugs. First, this technology provides an alternative approach in the discovering new antibody drug candidates. Instead of going through a long and costly process to generate antibody from scratch, one can an assay to rapidly screening an antibody library or commercially available mAb antibodies to identifying an candidate. Second, with this technology, it become possible for a biogenetic company to rapidly create its own antibody expression clone with a small amount of commercially available antibodies. Third, this technology also provides the most conclusive way to confirm the primary amino acid sequence of therapeutic antibody product, since the conventional Peptide Mapping may fail to detect some mutated sequence. 

Please contact us if interested in our mAb De Novo sequencing service.

• Protein Mixture Quantitation & Impurity Analysis

• Peptide Mapping

• Disulfide Bond Analysis

• Glycosylation Analysis

• Intact Molecular Weight Measurement

• N-terminal and C-terminal Sequencing

• Electrophoresis and Isoelectric Focusing Analysis

• Liquid Chromatographic Analysis

• Colony Selection

• Antibody Epitope Mapping

• Identifying Antibody Molecular Targets

• Software for Characterizing Therapeutic Proteins

• Submit A Request